PRIMARY STUDY
The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis
Key Findings: In this study of mouse macrophages as a model of colonic inflammation found that cannabichromene (CBC) via the TRPA1 ligands had anti-inflammatory activity, and if targeted could provide therapeutic treatments for the inflammatory bowel disease and associated conditions.
Type of Study: Animal Study
Study Result: Positive
Study Location(s): Italy, United Kingdom
Year of Pub: 2021
Cannabinoids Studied: Cannabichromene (CBC), AM-x Synthetic Cannabinoids, JWH-x Synthetic Cannabinoids, HU-x Synthetic Cannabinoids, SR-x Synthetic Cannabinoids, Anandamide (AEA), 2-Arachidonoyl Glycerol (2-AG), Virodhamine (O-AEA), Synthetic Cannabinoid (unspecified), Pharma THC, Palmitoylethanolamide (PEA)
Phytocannabinoid Source: Unspecified
Receptors Studied: CB1, CB2, TRPA1
Ligands Studied: Anti-inflammatory cytokines, Pro-inflammatory cytokines
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration: In vitro
Cannabinoid Ratio: (CBC) 0 
Dosing Regimen: CBC (1 μM) CBC significantly cured experimental colitis at the 1 mg/kg daily dose CBC had statistically significant pharmacological actions starting from the 10 mg/kg dose
Treatment Duration: 30 minutes
Clinical Relevance: It appears feasible that cannabichromene (CBC) may limit tissue destruction caused by nitric oxide (NO) in autoimmune diseases by decreasing NO production. There is also evidence based on its curative effect on murine colitis in vivo, CBC is a promising candidate for clinical evaluation in inflammatory bowel disease.
Link to study
